Natus Medical Inc (BABY) Expected to Announce Quarterly Sales of $126.39 Million

Wall Street analysts expect Natus Medical Inc (NASDAQ:BABY) to post $126.39 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Natus Medical’s earnings. The highest sales estimate is $126.70 million and the lowest is $126.10 million. Natus Medical reported sales of $124.66 million during the same quarter last year, which indicates a positive year over year growth rate of 1.4%. The company is scheduled to announce its next quarterly earnings results before the market opens on Wednesday, April 25th.

On average, analysts expect that Natus Medical will report full year sales of $126.39 million for the current financial year, with estimates ranging from $536.30 million to $537.82 million. For the next fiscal year, analysts forecast that the company will post sales of $557.27 million per share, with estimates ranging from $548.60 million to $565.93 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Natus Medical.

How to Become a New Pot Stock Millionaire

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.54 by ($0.12). The firm had revenue of $131.40 million for the quarter, compared to analysts’ expectations of $131.38 million. Natus Medical had a negative net margin of 4.05% and a positive return on equity of 11.36%. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.51 EPS.

BABY has been the subject of several research analyst reports. Zacks Investment Research cut Natus Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, January 11th. BidaskClub cut Natus Medical from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. William Blair cut Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Roth Capital set a $39.00 target price on Natus Medical and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, Benchmark reiterated a “buy” rating and issued a $49.00 target price (down previously from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $44.33.

In other news, Director Ken Ludlum sold 4,000 shares of Natus Medical stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $31.68, for a total value of $126,720.00. Following the completion of the transaction, the director now owns 93,825 shares in the company, valued at approximately $2,972,376. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.50% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its holdings in Natus Medical by 54.4% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,245 shares of the medical equipment provider’s stock valued at $647,000 after acquiring an additional 6,073 shares during the period. Sei Investments Co. boosted its holdings in Natus Medical by 149.9% during the 3rd quarter. Sei Investments Co. now owns 7,952 shares of the medical equipment provider’s stock valued at $298,000 after acquiring an additional 4,770 shares during the period. Municipal Employees Retirement System of Michigan boosted its holdings in Natus Medical by 60.1% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 12,420 shares of the medical equipment provider’s stock valued at $466,000 after acquiring an additional 4,660 shares during the period. Rhumbline Advisers boosted its holdings in Natus Medical by 2.5% during the 3rd quarter. Rhumbline Advisers now owns 67,065 shares of the medical equipment provider’s stock valued at $2,515,000 after acquiring an additional 1,620 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Natus Medical during the 3rd quarter valued at $138,000. Hedge funds and other institutional investors own 95.96% of the company’s stock.

NASDAQ BABY opened at $33.65 on Friday. The company has a market cap of $1,115.83, a price-to-earnings ratio of 23.21 and a beta of 0.55. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.32 and a quick ratio of 2.54. Natus Medical has a 1-year low of $28.00 and a 1-year high of $43.60.

Natus Medical declared that its Board of Directors has approved a share buyback program on Thursday, February 22nd that authorizes the company to repurchase $30.00 million in shares. This repurchase authorization authorizes the medical equipment provider to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

TRADEMARK VIOLATION WARNING: “Natus Medical Inc (BABY) Expected to Announce Quarterly Sales of $126.39 Million” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.wkrb13.com/2018/04/01/natus-medical-inc-baby-expected-to-announce-quarterly-sales-of-126-39-million.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply